aTyr Pharma, Inc. (NASDAQ:LIFE) posted its earnings results on Tuesday. The biotechnology company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.07, Bloomberg Earnings reports.
aTyr Pharma (NASDAQ:LIFE) traded up $0.25 during trading hours on Wednesday, hitting $3.95. The company had a trading volume of 12,805 shares, compared to its average volume of 106,687. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.13 and a quick ratio of 6.13. aTyr Pharma has a 12-month low of $2.10 and a 12-month high of $6.50.
COPYRIGHT VIOLATION NOTICE: “aTyr Pharma, Inc. (LIFE) Announces Earnings Results” was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.truebluetribune.com/2017/11/15/atyr-pharma-inc-life-announces-earnings-results.html.
In other news, CEO John Mendlein purchased 37,736 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was bought at an average cost of $2.65 per share, with a total value of $100,000.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Paul Schimmel purchased 94,336 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were purchased at an average cost of $2.65 per share, with a total value of $249,990.40. Following the completion of the purchase, the director now owns 40,440 shares of the company’s stock, valued at approximately $107,166. The disclosure for this purchase can be found here. Company insiders own 33.30% of the company’s stock.
A number of research analysts have weighed in on the company. BMO Capital Markets set a $4.00 target price on aTyr Pharma and gave the company a “hold” rating in a report on Tuesday, August 15th. Zacks Investment Research cut aTyr Pharma from a “buy” rating to a “hold” rating and set a $3.25 price target for the company. in a research report on Wednesday, August 30th. Finally, ValuEngine cut aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company’s stock. aTyr Pharma has a consensus rating of “Hold” and an average price target of $4.62.
About aTyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.